BIIB
HealthcareBiogen Inc. · Drug Manufacturers - General · $29B
What is Biogen Inc.?
Biogen Inc. is a large-cap biopharmaceutical company focused on discovering and delivering therapies for serious neurological and neurodegenerative diseases, headquartered in Cambridge, Massachusetts.
Biogen generates revenue by developing, manufacturing, and commercializing treatments for conditions including multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The company also markets biosimilars and maintains a pipeline spanning neurology, immunology, and neuropsychiatry, targeting some of the most difficult-to-treat conditions in medicine.
Founded in 1991, Biogen is based in Cambridge, US.
- Multiple sclerosis therapies (TECFIDERA, TYSABRI, AVONEX, PLEGRIDY, VUMERITY)
- Spinal muscular atrophy treatment (SPINRAZA)
- Alzheimer's disease programs (ADUHELM, Lecanemab/Aducanumab)
- Biosimilars portfolio (BENEPALI, IMRALDI, FLIXABI)
Is BIIB a Good Stock to Buy?
UQS Score rates BIIB as Good overall.
Biogen's most favorable attributes are its Attractive valuation relative to peers and a Good risk profile, suggesting the market may not be fully pricing in the company's asset base. Risk management appears above average for the sector.
Growth is rated Weak, reflecting near-term revenue headwinds, while Quality and Moat are both Neutral, indicating no standout competitive advantage at this time.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BIIB pay dividends?
No — Biogen Inc. does not currently pay a dividend.
Biogen does not currently pay a dividend. The company reinvests capital into its research pipeline and clinical programs, prioritizing long-term drug development over near-term income distribution — a common approach among biopharmaceutical companies with active pipelines.
When does BIIB report earnings?
Biogen reports earnings on a quarterly cadence, typical for US-listed equities.
Revenue trends have reflected pressure on legacy MS franchises alongside early-stage contributions from newer programs. Pipeline progress and partnership milestones tend to be key focal points each quarter.
For the most recent quarter's results, see Biogen's investor relations page at investors.biogen.com.
BIIB Price History
-30.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Biogen Inc.?
Based on Biogen Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Biogen do?
Biogen discovers, develops, and commercializes therapies for neurological and neurodegenerative diseases. Its marketed portfolio covers multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, alongside a biosimilars business and a broad clinical pipeline.
Does BIIB pay dividends?
No, Biogen does not pay a dividend. The company channels capital back into research and development rather than distributing income to shareholders, which is typical for biopharmaceutical companies with large, active pipelines.
When does BIIB report earnings?
Biogen reports on a quarterly basis. Specific upcoming dates are not covered by our data source — check Biogen's investor relations page for the current earnings calendar.
Is BIIB a good stock to buy?
UQS Score rates BIIB as Good overall, with an Attractive valuation and Good risk profile as standout positives. Growth is rated Weak, which is a meaningful consideration. The full pillar breakdown is available to Pro members.
Is BIIB overvalued?
Based on the UQS Valuation pillar, BIIB is rated Attractive, suggesting the stock may be trading at a discount relative to its fundamental profile. View the complete valuation analysis by signing up for UQS Pro.
What is BIIB's market cap bracket?
Biogen is classified as a large-cap company, placing it among the more established players in the biopharmaceutical sector by market size.
Who founded Biogen?
Biogen was founded in 1978 by a group of prominent scientists including Phillip Sharp and Walter Gilbert, though the current corporate entity reflects subsequent mergers and restructurings. The company has been headquartered in Cambridge, US, for many years.
Is BIIB a long-term quality stock?
As a long-term quality indicator, BIIB's Neutral Moat and Weak Growth ratings suggest the company faces real challenges sustaining competitive advantages over time. The Attractive valuation and Good risk profile may offer some cushion. Pro members can view the full multi-pillar analysis.
Unlock Full BIIB Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across Quality, Growth, Moat, Risk, and Valuation
- ✓Access detailed financial metrics behind each pillar score
- ✓Compare BIIB against sector peers on a standardized scoring framework
- ✓Get the full analyst-grade view in one place
Pro Analysis
BIIB — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 52.3 | 55.2 | 42.0 | 25.4 | 69.7 | 82.9 | -0.2 |
| May 22, 2026 | 52.5 | 55.2 | 42.0 | 25.4 | 69.7 | 84.4 | -0.1 |
| May 21, 2026 | 52.6 | 55.2 | 42.0 | 25.4 | 69.7 | 85.1 | +0.1 |
| May 20, 2026 | 52.5 | 55.2 | 42.0 | 25.4 | 69.7 | 84.6 | +0.2 |
| May 19, 2026 | 52.3 | 55.2 | 42.0 | 25.2 | 69.7 | 83.6 | 0.0 |
| May 17, 2026 | 52.3 | 55.2 | 42.0 | 25.2 | 69.7 | 83.4 | -0.1 |
| May 16, 2026 | 52.4 | 55.2 | 42.0 | 25.2 | 69.7 | 84.2 | -0.2 |
| May 15, 2026 | 52.6 | 55.2 | 42.0 | 25.2 | 69.7 | 85.6 | +0.3 |
| May 14, 2026 | 52.3 | 55.2 | 42.0 | 25.2 | 69.7 | 83.5 | -0.5 |
| May 13, 2026 | 52.8 | 55.2 | 42.0 | 25.2 | 69.7 | 86.5 | 0.0 |
BIIB — Pillar Breakdown
Quality
— 55.2/100 (25%)Biogen Inc. shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 25.4/100 (20%)Biogen Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 69.7/100 (15%)Biogen Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 84.3/100 (15%)Biogen Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 42/100 (25%)Biogen Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BIIB.
Score Composition
Financial Data
More Stock Analysis
How is the BIIB UQS Score Calculated?
The UQS (Unified Quality Score) for Biogen Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Biogen Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Biogen Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.